Custom Index Systems LLC Buys 262 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Custom Index Systems LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,377 shares of the company’s stock after purchasing an additional 262 shares during the period. Custom Index Systems LLC’s holdings in Medpace were worth $567,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rise Advisors LLC acquired a new stake in Medpace during the 1st quarter valued at $27,000. Mather Group LLC. acquired a new stake in Medpace during the 1st quarter valued at $28,000. Fidelis Capital Partners LLC acquired a new stake in Medpace during the 1st quarter valued at $31,000. DT Investment Partners LLC acquired a new stake in Medpace during the 2nd quarter valued at $41,000. Finally, J.Safra Asset Management Corp increased its holdings in Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Down 3.4 %

Shares of Medpace stock opened at $335.74 on Friday. Medpace Holdings, Inc. has a 12 month low of $227.21 and a 12 month high of $459.77. The business has a fifty day simple moving average of $390.71 and a 200 day simple moving average of $395.39. The stock has a market cap of $10.40 billion, a PE ratio of 34.22, a price-to-earnings-growth ratio of 1.85 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.93 earnings per share. Analysts expect that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, July 23rd. Truist Financial began coverage on Medpace in a research note on Thursday, August 1st. They issued a “hold” rating and a $415.00 target price for the company. Mizuho began coverage on Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price for the company. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $423.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.